Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644502 | 0.82 | MGLL (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL20644563 | 0.81 | MAPT (0.37) | ACACBEGLN1LMNASMN1; SMN2 | |
| SCHEMBL25160279 | 0.81 | MAPT (0.37) | ACACBEGLN1LMNASMN1; SMN2 | |
| SCHEMBL20644385 | 0.78 | PRMT5 (0.38) | — | |
| SCHEMBL25160112 | 0.72 | RGS4 (0.34) | LMNASMN1; SMN2 | |
| SCHEMBL20644471 | 0.72 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL20644462 | 0.69 | — | — | |
| SCHEMBL20644439 | 0.67 | PRMT5 (0.37) | — | |
| SCHEMBL25160128 | 0.67 | PPARG (0.34) | ACACBEGLN1LMNASMN1; SMN2 | |
| SCHEMBL25160125 | 0.67 | MAPT (0.37) | LMNASMN1; SMN2PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ACACB 1141/4885EGLN1 3567/4885LMNA 4266/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | ACACB 1141/4885EGLN1 3567/4885LMNA 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.